Polio vaccine

Types and characteristics

Two main vaccine types are in routine use: the inactivated poliovirus vaccine (IPV) and the oral poliovirus vaccine (OPV). Each uses a different approach to stimulate immunity.

• IPV (inactivated vaccine): contains killed poliovirus administered by injection. It induces strong bloodstream (systemic) immunity that prevents paralytic disease and cannot cause vaccine-derived infection because the virus is inactivated.
• OPV (oral, live-attenuated vaccine): given by mouth and contains weakened poliovirus strains. It produces both systemic and intestinal immunity, reducing virus shedding and transmission in communities. OPV is easier to deliver in mass campaigns and is less expensive, but in rare cases the weakened virus can mutate and cause vaccine-associated paralytic polio (VAPP) or circulating vaccine-derived poliovirus (cVDPV) when population immunity is low.

Programmes often use a combination of vaccine choices depending on local risk, cost, and the stage of eradication. Both types require cold-chain storage and multiple doses to achieve lasting protection.

History and development

The first widely adopted polio vaccine was developed by Jonas Salk and introduced in the 1950s as an injected inactivated product; its mass use began after public trials and an announcement in 1955 (Jonas Salk). A few years later Albert Sabin created an oral, live-attenuated vaccine whose large-scale human testing began in the late 1950s and whose formulation became licensed and widely used in the 1960s (Albert Sabin; early human trials were central to its rollout). These two discoveries offered complementary tools: Salk's vaccine avoided the risk of vaccine-derived infection while Sabin's approach made community-wide interruption of virus transmission more achievable.

Poliovirus exists as three antigenic serotypes (commonly called types 1, 2 and 3). Global control efforts, led by health organizations and national programmes, tailored vaccine use to eliminate each serotype in turn. Over decades immunization campaigns have driven case counts from hundreds of thousands annually to a small fraction of that number in many regions; for example, worldwide reported cases fell dramatically from the late 20th century into the 21st century.

Uses, impact and challenges

Routine childhood immunization and targeted mass campaigns are the primary uses of polio vaccines. Broad coverage reduces both the risk of paralytic disease and the circulation of wild poliovirus. Vaccination campaigns have prevented millions of cases of paralysis and are the keystone of the Global Polio Eradication Initiative and national public health strategies.

Challenges remain. OPV’s rare potential to revert and cause cVDPV requires high immunization coverage and careful surveillance. Maintaining cold chains, reaching underserved populations, and ensuring accurate disease surveillance are operational hurdles. Because poliovirus has no long-term nonhuman reservoir, elimination is feasible if human transmission is interrupted everywhere — but that requires coordinated, sustained effort.

Notable distinctions and facts

• IPV cannot cause vaccine-derived infection; OPV can, albeit rarely.
• OPV is favored for rapid interruption of transmission in outbreak settings because it induces intestinal immunity and is simple to give.
• Surveillance for acute flaccid paralysis and environmental sampling of sewage are key tools to detect ongoing virus circulation.

Polio vaccination remains one of the most influential public health interventions of the modern era: its technologies, policies, and global campaigns offer a model for controlling and potentially eradicating other infectious diseases.